Ian Mortimer
PRESIDENT & CEO at Xenon Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Xenon Pharmaceuticals Inc., 3 years.
Xenon Pharmaceuticals Inc.
Director · PRESIDENT & CEO
Chief executive roles
Xenon Pharmaceuticals Inc.
· PRESIDENT & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −7,308 | $55.23 | $403,621 |
| Mar 12, 2026 | Xenon Pharmaceuticals Inc. | Option exercise | +12,500 | — | — |
| Mar 10, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −11,269 | $60.11 | $677,380 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Option exercise | +75,000 | $8.40 | $630,000 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −21,791 | $58.81 | $1,281,529 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −31,694 | $59.88 | $1,897,837 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −21,515 | $60.49 | $1,301,442 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Option exercise | +25,000 | $3.10 | $77,500 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −12,479 | $59.50 | $742,501 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −10,072 | $60.47 | $609,054 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −2,449 | $61.26 | $150,026 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Option exercise | +105,000 | $4.75 | $498,750 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −43,348 | $59.26 | $2,568,802 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Open-market sale | −61,652 | $60.08 | $3,704,052 |
| Mar 9, 2026 | Xenon Pharmaceuticals Inc. | Option exercise | +65,000 | $9.44 | $613,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.